Compare Walt Disney Co (DIS) vs Moderna, Inc. (MRNA) Price & Performance

Disney (DIS) trades at $95.87, up 0.25% with a P/E of 15.36 and strong earnings beats in recent quarters. The company shows robust fundamentals with $94.43B revenue and $12.40B net income in 2025, though technical indicators signal bearish momentum. Recent news highlights advertising opportunities with major events and regulatory challenges with the FCC.

Outlook remains positive with analyst consensus at $125.60 target, representing 31% upside. Key opportunities include sports broadcasting rights and theme park recovery, while risks involve box office performance and regulatory pressures. The stock offers value with improving profitability and strong cash flow generation.

Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.

While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.